MCID: BLD036
MIFTS: 51

Bile Duct Disease

Categories: Gastrointestinal diseases, Liver diseases

Aliases & Classifications for Bile Duct Disease

MalaCards integrated aliases for Bile Duct Disease:

Name: Bile Duct Disease 12 15
Bile Duct Diseases 44 45 74
Disorder of Bile Duct 12
Bile Duct Disorder 12

Classifications:



External Ids:

Disease Ontology 12 DOID:4138
MeSH 45 D001649
NCIt 51 C96716
UMLS 74 C0005395

Summaries for Bile Duct Disease

MedlinePlus : 44 Your liver makes a digestive juice called bile. Your gallbladder stores it between meals. When you eat, your gallbladder pushes the bile into tubes called bile ducts. They carry the bile to your small intestine. The bile helps break down fat. It also helps the liver get rid of toxins and wastes. Different diseases can block the bile ducts and cause a problem with the flow of bile: Gallstones, which can increase pressure in the gallbladder and cause a gallbladder attack. The pain usually lasts from one to several hours. Cancer Infections Birth defects, such as biliary atresia. It is the most common reason for liver transplants in children in the United States. Inflammation, which can cause scarring. Over time, this can lead to liver failure. NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary : Bile Duct Disease, also known as bile duct diseases, is related to common bile duct disease and cholangitis, and has symptoms including nausea and vomiting, constipation and abdominal pain. An important gene associated with Bile Duct Disease is GPT (Glutamic--Pyruvic Transaminase), and among its related pathways/superpathways are Metabolism and Synthesis of bile acids and bile salts. The drugs Vancomycin and Pinaverium have been mentioned in the context of this disorder. Affiliated tissues include liver, lung and pancreas, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Wikipedia : 77 A bile duct is any of a number of long tube-like structures that carry bile, and is present in most... more...

Related Diseases for Bile Duct Disease

Diseases in the Bile Duct Disease family:

Common Bile Duct Disease

Diseases related to Bile Duct Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 98)
# Related Disease Score Top Affiliating Genes
1 common bile duct disease 34.3 CCK GGT2
2 cholangitis 32.4 ABCB11 ABCB4 ALB CEACAM5 GGT1 GPT
3 sclerosing cholangitis 30.6 ABCB11 ABCB4 ALB GGT1 NR1H4
4 cholangitis, primary sclerosing 30.5 ABCB4 ALB GGT1 GPT KRT19
5 intrahepatic cholangiocarcinoma 30.3 AFP KRT19 KRT7
6 cholangiocarcinoma 30.0 AFP CEACAM5 GGT1 KRT19 KRT7
7 caroli disease 11.1
8 atp8b1 deficiency 10.5 ABCB11 ATP8B1 NR1H4
9 cholestasis, progressive familial intrahepatic, 4 10.5 ABCB11 ABCB4 ATP8B1
10 cholestasis, progressive familial intrahepatic, 3 10.5 ABCB11 ABCB4 ATP8B1
11 alagille syndrome 1 10.5 ABCB11 ABCB4 ATP8B1
12 cholestasis, benign recurrent intrahepatic, 1 10.5 ABCB11 ATP8B1 SLC10A1
13 cholecystolithiasis 10.5 ABCB4 CCK
14 choledocholithiasis 10.5 ABCB4 ALB GPT
15 hyperbilirubinemia, rotor type 10.5 ABCC2 ALB
16 ovarian germ cell cancer 10.5 AFP KRT7
17 cyclosporiasis 10.5 GGT1 GGT2
18 intratubular embryonal carcinoma 10.5 AFP KRT7
19 proliferating trichilemmal cyst 10.5 KRT19 KRT7
20 cutaneous mucoepidermoid carcinoma 10.5 CEACAM5 KRT7
21 hepatic encephalopathy 10.5 ALB GPT SLC25A13
22 algoneurodystrophy 10.5 GGT1 GGT2
23 mucinous cystadenofibroma 10.4 AFP CEACAM5
24 liver lymphoma 10.4 AFP CEACAM5
25 mucinous adenofibroma 10.4 CEACAM5 KRT7
26 malignant spiradenoma 10.4 CEACAM5 KRT7
27 periampullary adenoma 10.4 GGT1 GGT2
28 bile duct mucoepidermoid carcinoma 10.4 CEACAM5 KRT7
29 cholestasis, progressive familial intrahepatic, 2 10.4 ABCB11 ABCB4 ATP8B1 NR1H4
30 melanotic medulloblastoma 10.4 AFP CEACAM5
31 ethmoid sinus cancer 10.4 GGT1 GGT2
32 cholestasis, progressive familial intrahepatic, 1 10.4 ABCB11 ABCB4 ATP8B1 NR1H4
33 urachal adenocarcinoma 10.4 AFP CEACAM5
34 hepatitis a 10.4 AFP ALB GPT
35 nodular hidradenoma 10.4 CEACAM5 KRT7
36 hepatoid adenocarcinoma 10.4 AFP ALB
37 ethmoid sinus adenocarcinoma 10.4 GGT1 GGT2
38 kwashiorkor 10.4 ALB GPT
39 hematocele of tunica vaginalis testis 10.4 AFP CEACAM5
40 splenic tuberculosis 10.4 CEACAM5 KRT19
41 bladder carcinoma in situ 10.4 KRT19 KRT7
42 vulval paget's disease 10.4 CEACAM5 KRT7
43 malignant leydig cell tumor 10.4 KRT19 KRT7
44 adenoid basal cell carcinoma 10.4 CEACAM5 KRT7
45 pancreatic serous cystadenoma 10.4 CEACAM5 KRT7
46 nasal cavity adenocarcinoma 10.4 CCK KRT7
47 thymus adenocarcinoma 10.4 CEACAM5 KRT7
48 meibomian cyst 10.4 CEACAM5 KRT7
49 corneal abscess 10.4 KRT19 KRT7
50 hepatic coma 10.4 ALB GPT

Graphical network of the top 20 diseases related to Bile Duct Disease:



Diseases related to Bile Duct Disease

Symptoms & Phenotypes for Bile Duct Disease

UMLS symptoms related to Bile Duct Disease:


nausea and vomiting, constipation, abdominal pain, diarrhea, icterus, dyspepsia, heartburn, gastrointestinal gas

GenomeRNAi Phenotypes related to Bile Duct Disease according to GeneCards Suite gene sharing:

27 (show all 16)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-107 9.66 ABCC3
2 Increased shRNA abundance (Z-score > 2) GR00366-A-128 9.66 GGT2
3 Increased shRNA abundance (Z-score > 2) GR00366-A-130 9.66 ABCC3 GGT1 GGT2
4 Increased shRNA abundance (Z-score > 2) GR00366-A-131 9.66 GGT2
5 Increased shRNA abundance (Z-score > 2) GR00366-A-143 9.66 ABCB11 ABCC3 GGT1 GGT2
6 Increased shRNA abundance (Z-score > 2) GR00366-A-146 9.66 ABCC3
7 Increased shRNA abundance (Z-score > 2) GR00366-A-169 9.66 GGT1
8 Increased shRNA abundance (Z-score > 2) GR00366-A-174 9.66 ABCC3
9 Increased shRNA abundance (Z-score > 2) GR00366-A-176 9.66 ABCC3
10 Increased shRNA abundance (Z-score > 2) GR00366-A-208 9.66 ABCC3
11 Increased shRNA abundance (Z-score > 2) GR00366-A-23 9.66 ABCB11
12 Increased shRNA abundance (Z-score > 2) GR00366-A-24 9.66 GGT2
13 Increased shRNA abundance (Z-score > 2) GR00366-A-54 9.66 ABCB11
14 Increased shRNA abundance (Z-score > 2) GR00366-A-7 9.66 GGT1 GGT2
15 Increased shRNA abundance (Z-score > 2) GR00366-A-88 9.66 ABCB11
16 Increased shRNA abundance (Z-score > 2) GR00366-A-9 9.66 ABCB11

MGI Mouse Phenotypes related to Bile Duct Disease:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.77 ABCB11 ABCB4 ABCC2 ABCC3 AFP ALB
2 liver/biliary system MP:0005370 9.32 ABCB11 ABCB4 ABCC2 ABCC3 AFP ALB

Drugs & Therapeutics for Bile Duct Disease

Drugs for Bile Duct Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 402)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Vancomycin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1404-90-6 14969 441141
2 Pinaverium Approved Phase 4,Not Applicable 59995-65-2
3
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
4
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 2078-54-8 4943
5
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
6
Midazolam Approved, Illicit Phase 4,Not Applicable 59467-70-8 4192
7
Etomidate Approved Phase 4 33125-97-2 667484 36339
8
Pancrelipase Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 53608-75-6
9
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
10
Ursodeoxycholic acid Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 128-13-2 31401
11
chenodeoxycholic acid Approved Phase 4,Phase 3,Phase 2,Early Phase 1 474-25-9 10133
12
Morphine Approved, Investigational Phase 4,Phase 2 57-27-2 5288826
13
Secretin Approved Phase 4 108153-74-8
14
Neostigmine Approved, Vet_approved Phase 4 59-99-4 4456
15
Meloxicam Approved, Vet_approved Phase 4 71125-38-7 54677470 5281106
16
Metronidazole Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 443-48-1 4173
17
Meperidine Approved Phase 4,Not Applicable 57-42-1 4058
18
Abatacept Approved Phase 4 332348-12-6 10237
19
Ceftriaxone Approved Phase 4,Phase 2 73384-59-5 5479530 5361919
20
Ofloxacin Approved Phase 4 82419-36-1 4583
21
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
22
Sorbitol Approved Phase 4 50-70-4 5780
23 Coconut Approved Phase 4
24
Tocopherol Approved, Investigational Phase 4 1406-66-2 14986
25
Calcium Approved, Nutraceutical Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 7440-70-2 271
26
Choline Approved, Nutraceutical Phase 4 62-49-7 305
27
Methionine Approved, Nutraceutical Phase 4,Phase 3,Phase 2 63-68-3 6137
28
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4 59-02-9 14985
29 Tocotrienol Investigational Phase 4 6829-55-6
30 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
31 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
32 Calcium, Dietary Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
33 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
34 Bromides Phase 4,Phase 3,Not Applicable
35 Parasympatholytics Phase 4,Phase 3,Not Applicable
36 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
37 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
38 calcium channel blockers Phase 4,Not Applicable
39 Anticonvulsants Phase 4,Phase 3,Not Applicable
40 Anesthetics, General Phase 4,Phase 3,Phase 2,Not Applicable
41 Hydrocortisone hemisuccinate Phase 4
42 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Not Applicable
43 GABA Modulators Phase 4,Not Applicable
44 Adjuvants, Anesthesia Phase 4,Phase 3
45 Anesthetics Phase 4,Phase 3,Phase 2,Not Applicable
46 Anesthetics, Intravenous Phase 4,Phase 3,Phase 2,Not Applicable
47 Anti-Anxiety Agents Phase 4,Phase 3
48 Hydrocortisone 17-butyrate 21-propionate Phase 4
49 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
50 Psychotropic Drugs Phase 4,Phase 3,Phase 2

Interventional clinical trials:

(show top 50) (show all 591)
# Name Status NCT ID Phase Drugs
1 Effect and Safety of Oral Vancomycin in Primary Sclerosing Cholangitis Patients Unknown status NCT02605213 Phase 4 Vancomycin;Placebo
2 Pinaverium Bromide in Post-cholecystectomy Sphincter of Oddi Dysfunction Unknown status NCT02833103 Phase 4 Danshu Capsules;Pinaverium Bromide
3 Endoscopic Treatment of Difficult Bile Duct Stones: Spyglass + EHL x Balloon Dilation of the Papilla Unknown status NCT02703077 Phase 4
4 Uncovered Self-expandable Metal Stent Versus Double Layer Plastic Stent for Malignant Hilar Stricture Unknown status NCT01125865 Phase 4
5 Effects of Etomidate on Postoperative Circadian Rhythm Changes of Salivary Cortisol in Children Unknown status NCT02013986 Phase 4 etomidate;midazolam;propofol
6 Efficacy and Safety of S-adenosyl-l-methionine in Treatment of Alcoholic Hepatitis With Cholestasis Unknown status NCT02024295 Phase 4 Ademethionine;Polyene Phosphatidyl choline;Ademethionine
7 Efficacy and Safety of S-adenosyl-L-methionine in Treatment of Chronic Hepatitis B Patients With Cholestasis Unknown status NCT01998620 Phase 4 Ademetionine 2;Ademetionine 1;Ademetionine 3
8 Additional Effects of Perioperative Immunonutrition in Patients Undergoing Pancreaticoduodenectomy Unknown status NCT01969110 Phase 4
9 Effects of Preoperative Immunonutrition in Patients Undergoing Hepatectomy Unknown status NCT01256047 Phase 4
10 Cyclooxygenase-2 Inhibitor for Adjuvant Anticancer Effect in Patients With Biliary-pancreas Cancer Unknown status NCT01111591 Phase 4 Cox2 inhibitor (Celecoxib)
11 The Usefulness of Endoscopic Ultrasound-guided Biliary Drainage With a Newly Designed Hybrid Metallic Stent Completed NCT01862198 Phase 4
12 A Study of Serial Magnetic Resonance Cholangiopancreatography (MRCP) Following Morphine-neostigmine and Secretin Provocation in Healthy Volunteers Completed NCT01134848 Phase 4 Morphine;Neostigmine;0.9% saline;Secretin;0.9% saline
13 Clinical Study About the Role of COX-2 Inhibitor in Liver Cirrhosis With Biliary Atresia Completed NCT02298218 Phase 4 Meloxicam
14 DGT Versus TPS in Patients With Initial PD Cannulation by Chance; Prospective Multi-center Study Completed NCT01744847 Phase 4
15 Etomidate vs. Midazolam for Sedation During ERCP Completed NCT02027311 Phase 4 Etomidate;Midazolam;Meperidine
16 Preventing Cholestasis Using SMOFLipid® Completed NCT01585935 Phase 4 SMOFLIPID;INTRALIPID
17 Effectiveness of S-adenosyl-L-methionine in Patients With Primary Biliary Cirrhosis Completed NCT02557360 Phase 4
18 Study of Abatacept (Orencia) to Treat Primary Biliary Cirrhosis Completed NCT02078882 Phase 4
19 Ursofalk Tablets (500 mg) Versus Ursofalk Capsules (250 mg) in the Treatment of Primary Biliary Cirrhosis Completed NCT01510860 Phase 4 UDCA (Ursodeoxycholic acid);UDCA (Ursodeoxycholic acid)
20 Effects of Preoperative Immunonutrition in Patients Undergoing Pancreaticoduodenectomy Completed NCT01256034 Phase 4
21 Comparing Covered Self-expandable Metallic Stent (SEMS) Above/Across the Sphincter of Oddi Completed NCT01041612 Phase 4
22 Biliary Metal Stent Study: Metal Stents for Management of Distal Malignant Biliary Obstruction Completed NCT00280709 Phase 4
23 Antibiotics to Decrease Post ERCP Cholangitis Recruiting NCT03087656 Phase 4 Ceftriaxone;Levofloxacin
24 Study of OCA Evaluating Pharmacokinetics and Safety in Patients With PBC and Hepatic Impairment Recruiting NCT03633227 Phase 4 Obeticholic Acid (OCA);Placebo
25 A Trial of 18-22mg/kg/d Ursodeoxycholic in Refractory Primary Biliary Cholangitis Recruiting NCT03345589 Phase 4 18-22mg/kg/d Ursodeoxycholic;13-15mg/kg/d Ursodeoxycholic
26 Phase 4 Study of Obeticholic Acid Evaluating Clinical Outcomes in Patients With Primary Biliary Cholangitis Recruiting NCT02308111 Phase 4 Obeticholic Acid (OCA);Placebo
27 WallFlex Biliary Fully Covered (FC) Chronic Pancreatitis Study Active, not recruiting NCT01543256 Phase 4
28 Low Dose Fat for the Prevention of Liver Disease in Babies With Gastrointestinal Disorders Terminated NCT01373918 Phase 4 Intralipid;Intralipid
29 Reduction of Neonatal Parenteral Nutrition Associated Cholestasis Through Lipid Emulsions Terminated NCT02633384 Phase 4
30 The INFECIR-2 Albumin Prevention Study Terminated NCT02034279 Phase 4 Albumin
31 Compare the Knob-tipped Knife With the Needle Knife in Difficult Biliary Cannulation Unknown status NCT01745978 Phase 3
32 RCT of Steroids Following Kasai Portoenterostomy for Biliary Atresia. Unknown status NCT00539565 Phase 3 prednisolone;placebo
33 Minimization of IntraLipid Versus Omegaven Unknown status NCT01247012 Phase 2, Phase 3
34 Probiotics in Patients With Primary Sclerosing Cholangitis Unknown status NCT00161148 Phase 3 Probiotics
35 Comparison of Endoscopic Radiofrequency Ablation Versus Photodynamic Therapy for Inoperable Cholangiocarcinoma Unknown status NCT01739465 Phase 2, Phase 3
36 Short-term Stenting Versus Balloon Dilatation for Dominant Strictures in Primary Sclerosing Cholangitis Unknown status NCT01398917 Phase 3
37 WallFlex Biliary Fully Covered (FC) Benign Stricture Study Unknown status NCT01014390 Phase 3
38 The Effect of Bezafibrate on Cholestatic Itch Unknown status NCT02701166 Phase 3 Bezafibrate;Placebo
39 Fuzhenghuayu for Patients With PBC Who Had An Inadequate Response to Ursodeoxycholic Acid Unknown status NCT02916641 Phase 3 Fuzhenghuayu;UDCA
40 Fuzhenghuayu in Combination With Ursodeoxycholic Acid in Primary Biliary Cirrhosis Unknown status NCT02916290 Phase 3 Fuzhenghuayu;UDCA
41 Fenofibrate for Patients With Primary Biliary Cirrhosis Who Had An Inadequate Response to Ursodeoxycholic Acid Unknown status NCT02823366 Phase 3 Fenofibrate;UDCA
42 Fenofibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cirrhosis Unknown status NCT02823353 Phase 3 Fenofibrate;UDCA
43 Photodynamic Therapy (PDT) for Palliation of Cholangiocarcinoma Unknown status NCT01755013 Phase 2, Phase 3
44 Early Enteral Feeding After Pylorus Preserving Pancreatoduodenectomy Unknown status NCT00809081 Phase 3
45 Newly Designed Fully Covered Metal Stent for the Benign Biliary Stricture Completed NCT00945516 Phase 3
46 Drotaverine Hydrochloride Versus Hyoscine-N-butylbromide for Duodenal Antimotility During Endoscopic Retrograde Cholangiopancreatography (ERCP) Completed NCT00731198 Phase 3 Drotaverine hydrochloride;Hyoscine-N-butylbromide
47 Digital SpyGlass Confirmed Common Bile Duct Stones Clearance Without Fluoroscopy Completed NCT02967926 Phase 3
48 Duloxetine in Patients With Suspected Functional Pancreatic/Biliary Pain (Sphincter of Oddi Dysfunction) Completed NCT00471315 Phase 3 Duloxetine
49 Effectiveness of Multicomponent Lipid Emulsion in Preterm Infants Requiring Parenteral Nutrition Completed NCT02663453 Phase 3 multicomponent lipid emulsion;pure soybean oil lipid emulsion
50 Intravenous Fat Emulsion Comprised of Fish Oil in the Treatment of Parenteral Nutrition Induced Liver Injury in Infants Completed NCT02534077 Phase 3 Omegaven;Omegaven;Omegaven

Search NIH Clinical Center for Bile Duct Disease

Cochrane evidence based reviews: bile duct diseases

Genetic Tests for Bile Duct Disease

Anatomical Context for Bile Duct Disease

MalaCards organs/tissues related to Bile Duct Disease:

42
Liver, Lung, Pancreas, Kidney, Testes, Bone, Small Intestine

Publications for Bile Duct Disease

Articles related to Bile Duct Disease:

(show all 29)
# Title Authors Year
1
Comparison of digital versus fiberoptic cholangioscopy in patients requiring evaluation of bile duct disease or treatment of biliary stones. ( 30837794 )
2019
2
Gallbladder and bile duct disease in Cystic Fibrosis. ( 28986023 )
2017
3
Comparative MRI analysis of morphologic patterns of bile duct disease in IgG4-related systemic disease versus primary sclerosing cholangitis. ( 24555589 )
2014
4
Cholangioscopy in bile duct disease: a case series. ( 25296087 )
2014
5
Echinococcosis mimicking autoimmune or malignant bile duct disease. ( 24022203 )
2013
6
Peripheral intrahepatic cholangiocarcinoma occurring in patients without cirrhosis or chronic bile duct diseases: epidemiology and histopathology of distant nontumoral liver in 57 White patients. ( 23085575 )
2013
7
Single-operator cholangioscopy in patients requiring evaluation of bile duct disease or therapy of biliary stones (with videos). ( 21762903 )
2011
8
Biliary cytokeratin expression but not CD56 (N-CAM) expression aids in the differential diagnosis of non-neoplastic bile duct diseases. ( 20538416 )
2010
9
Extensive hilar bile duct resection using a transhepatic approach for patients with hepatic hilar bile duct diseases. ( 18466867 )
2008
10
Sonographic diagnosis of extrahepatic bile duct diseases using a physiologic saline retention enema. ( 16944491 )
2006
11
Expression and localization of ecto-nucleotide pyrophosphatase/phosphodiesterase I-1 (E-NPP1/PC-1) and -3 (E-NPP3/CD203c/PD-Ibeta/B10/gp130(RB13-6)) in inflammatory and neoplastic bile duct diseases. ( 15072822 )
2004
12
Combined laparoscopic and endoscopic treatment for bile duct diseases. ( 15138127 )
2004
13
Treatment of extrahepatic bile duct disease in infancy and early childhood. ( 11847446 )
2002
14
Modalities of testing Helicobacter pylori in patients with nonmalignant bile duct diseases. ( 11925612 )
2002
15
Detection of Helicobacter DNA in bile from bile duct diseases. ( 10331565 )
1999
16
New approach in diagnosis of bile duct disease with ultrasound and magnetic resonance imaging. ( 28976650 )
1998
17
Histopathology of vanishing bile duct diseases. ( 10358336 )
1998
18
Effect of ursodeoxycholic acid on liver and bile duct disease in primary sclerosing cholangitis. A 3-year pilot study with a placebo-controlled study period. ( 8201224 )
1994
19
Bile duct disease: prospective comparison of ERCP, CT, and fat suppression MRI. ( 1426853 )
1992
20
Rejection of murine congenic bile ducts: a model for immune-mediated bile duct disease. ( 1537528 )
1992
21
Destructive intrahepatic bile duct diseases. ( 2251446 )
1990
22
Peroral cholangioscopy--an improved method in the diagnosis of common bile duct diseases. ( 2792678 )
1989
23
Primary sclerosing cholangitis, a vanishing bile duct disease. ( 3658059 )
1987
24
Radiomanometry in the diagnosis of common bile duct disease. ( 4445925 )
1974
25
Radiomanometry, flow rates, and cholangiography in the evaluation of common bile duct disease. A study of 220 cases. ( 5058873 )
1972
26
Radiologic aspects of bile duct diseases. ( 13405804 )
1957
27
The incidence of common bile duct disease following surgical exploration. ( 14352652 )
1955
28
Gallbladder and bile duct disease. ( 14392255 )
1955
29
Paper electrophoresis in the diagnostics of liver and bile duct diseases. ( 13048608 )
1952

Variations for Bile Duct Disease

Expression for Bile Duct Disease

Search GEO for disease gene expression data for Bile Duct Disease.

Pathways for Bile Duct Disease

Pathways related to Bile Duct Disease according to GeneCards Suite gene sharing:

(show all 11)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.86 ABCB11 ABCB4 ABCC3 ALB CYP7A1 GGT1
2
Show member pathways
12.04 ABCB11 ABCC3 ALB CYP7A1 NR1H4 SLC10A1
3 11.87 ABCC2 ABCC3 GGT1 GGT2
4
Show member pathways
11.76 ABCB11 ABCB4 ABCC2 SLC10A1
5 11.36 ABCB11 ABCB4 ABCC2 ABCC3 CYP7A1 NR1H4
6 11.18 ABCB11 ABCB4 ABCC2 ABCC3 CYP7A1 NR1H4
7 10.93 ABCB11 ABCB4 CYP7A1 NR1H4 SLC10A1
8
Show member pathways
10.8 ABCC2 ABCC3
9 10.71 ABCC2 ABCC3
10 10.43 ABCC2 ABCC3
11 10.33 ABCB11 ABCC2 ABCC3 CYP7A1 NR1H4 SLC10A1

GO Terms for Bile Duct Disease

Cellular components related to Bile Duct Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.76 ABCB11 ABCB4 ABCC2 ABCC3 ATP8B1 CEACAM5
2 extracellular exosome GO:0070062 9.65 ABCB11 ABCB4 ALB CEACAM5 GGT1 GGT2
3 apical plasma membrane GO:0016324 9.56 ABCB4 ABCC2 ATP8B1 CEACAM5
4 intercellular canaliculus GO:0046581 8.8 ABCB11 ABCB4 ABCC2

Biological processes related to Bile Duct Disease according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 transmembrane transport GO:0055085 9.88 ABCB11 ABCB4 ABCC2 ABCC3 SLC10A1 SLC25A13
2 glutamate metabolic process GO:0006536 9.52 GGT1 GGT2
3 zymogen activation GO:0031638 9.51 GGT1 GGT2
4 bile acid metabolic process GO:0008206 9.49 ATP8B1 NR1H4
5 cysteine biosynthetic process GO:0019344 9.48 GGT1 GGT2
6 regulation of immune system process GO:0002682 9.46 GGT1 GGT2
7 regulation of bile acid biosynthetic process GO:0070857 9.43 CYP7A1 NR1H4
8 glutathione catabolic process GO:0006751 9.43 GGT1 GGT2 GGTLC3
9 peptide modification GO:0031179 9.37 GGT1 GGT2
10 leukotriene D4 biosynthetic process GO:1901750 9.33 GGT1 GGT2 GGTLC3
11 drug transmembrane transport GO:0006855 9.32 ABCC2 ATP8B1
12 canalicular bile acid transport GO:0015722 9.13 ABCB11 ABCC2 ABCC3
13 bile acid and bile salt transport GO:0015721 9.02 ABCB11 ABCC3 ATP8B1 NR1H4 SLC10A1

Molecular functions related to Bile Duct Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 ATPase activity GO:0016887 9.62 ABCB11 ABCB4 ABCC2 ABCC3
2 organic anion transmembrane transporter activity GO:0008514 9.37 ABCC2 ABCC3
3 peptidyltransferase activity GO:0000048 9.26 GGT1 GGT2
4 ATPase activity, coupled to transmembrane movement of substances GO:0042626 9.26 ABCB11 ABCB4 ABCC2 ABCC3
5 bile acid-exporting ATPase activity GO:0015432 9.16 ABCB11 ABCC3
6 glutathione hydrolase activity GO:0036374 8.8 GGT1 GGT2 GGTLC3

Sources for Bile Duct Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....